Multi-modal medical images are important in tumor lesion detection. However, the existing detection models only use single-modal to detect lesions, a multi-modal semantic correlation is not enough to consider and lacks ability to express the shape, size, and contrast degree features of lesions. A Cross Modal YOLOv5 model (CMYOLOv5) is proposed. Firstly, there are two networks, auxiliary network is consisted by dual-branch structure to extract semantic information from PET and CT, backbone network is consisted by YOLOv5 to extract semantic information from PET/CT. Secondly, Cross-modal Features Fusion (CFF) is designed in auxiliary network to fuse PET functional information and CT anatomical information. Self-Adaptive Attention Fusion (AAF) is designed in backbone network to fuse and enhance three-modal complementary information. Thirdly, Self-Adaptive Transformer (SAT) is designed in feature enhance neck. Using Transformer with deformable attention mechanism to focus on lung tumor region. Using MLP with channel attention mechanism to enhance features representation ability of lung tumor region. Finally, Reparameter Residual Block (RRB) and Reparameter Convolution operation (RC) are designed to fully learn richer PET, CT and PET/CT feature. Comparative experiments are conducted on clinical lung tumor PET/CT multi-modality dataset, the effectiveness of CMYOLOv5 is verified by Precision, Recall, mAP, F1, FPS, and training time, experimental results are 97.16%, 96.41%, 97.18%, 96.78%, 96.37 and 3912 s. CMYOLOv5 has high precision in the detection of irregular lung tumors, which is superior to the existing advanced methods.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1038/s41598-024-79786-1 | DOI Listing |
Trends Cancer
December 2024
Herbert Irving Comprehensive Cancer Center, New York, NY, 10032, USA; Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, NY, 10032, USA; Division of Digestive and Liver Diseases, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, NY 10032, USA. Electronic address:
Metastasis is responsible for most cancer-related deaths. Different cancers have their own preferential sites of metastases, a phenomenon termed metastatic organotropism. The mechanisms underlying organotropism are multifactorial and include the generation of a pre-metastatic niche (PMN), metastatic homing, colonization, dormancy, and metastatic outgrowth.
View Article and Find Full Text PDFHematol Oncol Clin North Am
December 2024
Department of Radiation Oncology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA. Electronic address:
Circulating tumor DNA (ctDNA) is emerging as a transformative biomarker in the management of non-small cell lung cancer (NSCLC). This review focuses on its role in detecting minimal residual disease (MRD), predicting treatment response, and guiding therapeutic decision-making in radiation oncology and immunotherapy. Key studies demonstrate ctDNA's prognostic value, particularly in identifying relapse risk and refining patient stratification for curative-intent and consolidative treatments.
View Article and Find Full Text PDFCancer Lett
December 2024
Department of Anatomical and Cellular Pathology, State Key Laboratory of Translational Oncology, Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, Hong Kong; Peter Hung Pain Research Institute, The Chinese University of Hong Kong, Hong Kong. Electronic address:
J Thorac Oncol
December 2024
Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea. Electronic address:
Introduction: Treatment with adjuvant osimertinib for three years is the standard-of-care for resected stage IB-IIIA non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR)-mutations. The role of neoadjuvant osimertinib in the perioperative setting is yet to be elucidated in the NeoADAURA study (NCT04351555).
Methods: This is a single center, pilot study of patients with clinical stage IA-IIIA NSCLC (AJCC 8th edition) harboring an activating EGFR mutation (Exon 19 deletion, L858R) (NCT04816838).
Lung Cancer
December 2024
Department of Internal Medicine, Division of Hematology/Oncology, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indiana University School of Medicine (IUSOM), Indianapolis, IN 46202, USA. Electronic address:
A major paradigm shift in the diagnosis, management, and survival outcomes of early and advanced non-small cell lung cancer has transpired over the past few decades in thoracic oncology with the incorporation of molecular testing, targeted therapy, immunotherapy, neoadjuvant, and adjuvant approaches. However, transformation in the management and survival outcomes of rare lung tumors is lacking. Given the scarcity of these tumor types, randomized trials are rarely performed, and treatment is extrapolated from case series, tumor-agnostic trials, or cancers with similar histology.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!